Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atabecestat · 1 trial · 1 indication
Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response (via cluster of differentiation \[CD\] 4+ T-cells and CD8+ T-cells) will be determined.
| Arm | Type | Description |
|---|---|---|
| Participants with Elevated Liver Enzymes | EXPERIMENTAL | Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat. |
| Participants Without Elevated Liver Enzymes | ACTIVE_COMPARATOR | Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat. |
| Name | Type | Description |
|---|---|---|
| Atabecestat | DRUG | Blood samples will be collected from participants previously treated with atabecestat. |
Inclusion Criteria: * Participant who received and discontinued atabecestat in one of the following prior trials (54861911ALZ2002, 54861911ALZ2003, or 54861911ALZ2004) * Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the s...
Top 20 of 24 competitors
Atabecestat is an investigational small molecule being studied for the treatment of Alzheimer Disease. It is being developed by Johnson & Johnson (JNJ). The drug is in early clinical development, with a completed Phase 1 trial that characterized T-cell responses in participants previously treated with the drug.
Atabecestat is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational small molecule intended for the treatment of Alzheimer Disease and is currently in early-stage clinical development.
Atabecestat is in Phase 1 clinical development. A completed early Phase 1 trial, NCT03587376, evaluated the drug in participants with Alzheimer Disease. The drug is investigational and has not been approved by regulatory authorities, as it remains in clinical development.
Atabecestat has one completed clinical trial, NCT03587376, titled "Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)." This early Phase 1 study enrolled 9 participants with Alzheimer Disease across Belgium, France, Germany, Spain, and Sweden.
Yes, Atabecestat is also known as JNJ-54861911. The clinical trial NCT03587376 explicitly refers to the drug as JNJ-54861911 (Atabecestat), confirming that these names refer to the same investigational compound being developed for Alzheimer Disease.